Amgen issued a press release on October 26, 2026, announcing the appointment of David W. Gibbs to its Board of Directors, effective immediately, bringing total board membership to 13 directors.

Key Highlights

  • New director appointed: David W. Gibbs joins Amgen's Board of Directors effective immediately, according to the filing.
  • Committee assignments: Gibbs will serve on the Board's Audit Committee and Compensation and Management Development Committee.
  • Prior executive role: Gibbs recently retired as president and chief executive officer of Yum! Brands, a position he held from 2020 to 2025.
  • Board composition: With Gibbs' appointment, the Board will have 13 directors, 12 of whom are independent.
  • Existing board service: Gibbs has served on the Board of Directors of Under Armour, Inc. since 2021 and PepsiCo, Inc. since 2026.
  • Education: Gibbs holds a bachelor's degree in mathematical science from Johns Hopkins University and an MBA from Duke University's Fuqua School of Business.

Amgen Adds Former Yum! Brands CEO to Its Board

Amgen (NASDAQ:AMGN) announced on October 26, 2026, that David W. Gibbs has been appointed to its Board of Directors, effective immediately. According to the filing, Gibbs will serve on two board committees: the Audit Committee and the Compensation and Management Development Committee.

The filing describes Gibbs as having recently retired from Yum! Brands, where he served as president and chief executive officer from 2020 to 2025. During that period, the company disclosed, he "led the company's digital transformation and expanded its global footprint to nearly 61,000 locations." Yum! Brands is identified in the filing as "a worldwide leader in iconic restaurant brands, including Taco Bell and Kentucky Fried Chicken."

Beyond his executive background, the filing notes that Gibbs brings "significant board experience with leading global consumer brands." He has served on the Board of Directors of Under Armour, Inc. since 2021, where he chairs the Human Capital and Compensation Committee, and on the Board of PepsiCo, Inc. since 2026, where he serves on the Audit Committee. Robert A. Bradway, chairman and chief executive officer at Amgen, is quoted in the filing as stating that Gibbs' "experience creating direct relationships with customers will help inform how we prepare for future launches and bring innovative treatments to more patients around the world." The filing notes that with this appointment, Amgen's Board will consist of 13 directors, 12 of whom are independent.

What Was Disclosed

Amgen disclosed the appointment of David W. Gibbs to its Board of Directors, effective October 26, 2026, including his committee assignments, professional background at Yum! Brands, existing board roles at Under Armour and PepsiCo, and the resulting board composition of 13 directors.